LAXAF — Laxai Pharma Share Price
Last trade - 00:00- $0.01m
- $1.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -49.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2005 | 2006 | 2007 | 2008 | 2009 | 2010E | 2011E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.05 | 13.66 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -23.39 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Laxai Pharma, Ltd. (Laxai), formerly NexGen Biofuels Ltd., is a development-stage company. From March 2010, Laxai, through its fully owned subsidiary OSR Holding Corp., is engaged in the business of providing integrated services across the drug development spectrum out of Laxai subsidiary’s leased facilities in South Plainfield, New Jersey, United States of America. Laxai was engaged through February 2010, in the development and/or acquisition of ethanol and bio-diesel plants, and blending terminal facilities, in the United States. In February 2010, the Company ceased its ethanol and bio-diesel activities. On March 3, 2010, OSR Holding Corp. acquired all the assets of OSR Solutions, Inc. The Company focuses on offering medicinal chemistry, research & development processes, clinical research, collaborative research and blended onshore/off-shore model.
Directors
- Vamsi Maddipatla CHM
- Ram Upadhayaya CEO
- Nikhil Baheti CFO
- Ramesh Mullangi EVP
- Raghava Kethiri CSO
- Ganesh Venkatraman OTH
- Last Annual
- December 31st, 2009
- Last Interim
- September 30th, 2010
- Incorporated
- May 26th, 1988
- Public Since
- March 1st, 1989
- No. of Shareholders
- 104
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 63,378,751
- Address
- 8905 Regents Park Dr, Suite 210, TAMPA, 33647
- Web
- http://www.laxai.com/
- Phone
- +1 8134283500
- Auditors
- Barzily & Co.
Similar to LAXAF
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 01:13 UTC, shares in Laxai Pharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Laxai Pharma last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Laxai Pharma share price has underperformed the S&P500 Index by -12.47% over the past year.
There is no consensus recommendation for this security.
Laxai Pharma does not currently pay a dividend.
Laxai Pharma does not currently pay a dividend.
Laxai Pharma does not currently pay a dividend.
To buy shares in Laxai Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Laxai Pharma had a market capitalisation of $0.01m.
Here are the trading details for Laxai Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LAXAF
Based on an overall assessment of its quality, value and momentum Laxai Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laxai Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -6.92%.
As of the last closing price of $0.00, shares in Laxai Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Laxai Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Laxai Pharma's management team is headed by:
- Vamsi Maddipatla - CHM
- Ram Upadhayaya - CEO
- Nikhil Baheti - CFO
- Ramesh Mullangi - EVP
- Raghava Kethiri - CSO
- Ganesh Venkatraman - OTH